Date: 2012-06-04
Type of information: Grant
Company: Telormedix (Switzerland) Foamix (Israel)
Investors: European Eurostars Programme (EU)
Amount: € 950,000
Funding type: grant
Planned used: The grant will fund the two-year research project TOSCA. The TOSCA project’s main focus will be to develop an effective and safe topical treatment for skin cancer (dermatological cancers), actinic keratosis (AK) and genital warts by combining the target specific binding properties of TMX-202 with an innovative foam formulation to optimize skin penetration, drug delivery and patient compliance.
Others: Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, and Foamix Ltd have announced that they have raised funding from the European Eurostars Programme to coordinate a two-year international research project aimed at developing a new skin cancer topical treatment based on a foam formulation of one of the Company’s promising drug candidates, TMX-202. The project, operating under the acronym TOSCA, will have a total budget of just under € 950K. Two additional research teams will also be participating in this TOSCA project: Charité - Universitätsmedizin Berlin (Germany); and the German Cancer Research Center (DKFZ, Germany).
TMX-202 is a second generation TLR7 small molecule that has recently been selected for preclinical study for the topical treatment of skin cancers, bladder cancers and other indications. The candidate has already successfully completed a number of in vivo studies and was discovered through collaboration with the University of California San Diego.
Therapeutic area: Cancer - Oncology - Inflammatory diseases
